Virtual Library

Start Your Search

Y. Wu



Author of

  • +

    P1.07 - Poster Session/ Small Cell Lung Cancer (ID 221)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Small Cell Lung Cancer
    • Presentations: 1
    • +

      P1.07-004 - Efficacy of Endostar Combined with Chemotherapy and Endostar Maintenance Treatment for Patients with Extensive Small-Cell Lung Cancer (ID 1639)

      09:30 - 17:00  |  Author(s): Y. Wu

      • Abstract
      • Slides

      Background:
      EP scheme is a standard regimen ad the first-line treatment for small cell lung cancer, with the complete remission of 10~25% and overall survival up to 10 months. However, almost all patients reoccur or progress within 1 year after first-line treatment. Endostar combined with chemotherapy had synergistic effect and slight toxic effect.

      Methods:
      Patient, female, was admitted in the hospital in March, 2010 because of cough and hemoptysis and diagnosed as small cell lung cancer by bronchoscopic biopsy. Patient was finally diagnosed as extensive small-cell lung cancer by pathology and imaging (CT, MRI), who was treated by EP scheme (etoposide and cisplatin) and endostar for 6 months from July, 2010—Jan. 2011. Patient was remitted completely after treated by EP scheme (etoposide and cisplatin) and endostar. However, patients had brain metastases in Jan., 2011 and received radiotherapy and endostar maintenance treatment for 4 cycles. And patient was partially remitted. The reoccurrence of lung was considered in Nov., 2011 and treated by EP plus endostar for 2 cycles and patients was remitted completely until Feb., 2012.

      Results:
      During the course of treatment, patient was well tolerated to chemotherapy and had no intolerant toxic effects. Performance status of patients scored 0 point. Extra-cerebral progress Free Survival (PFS) reached 13 months and the follow up on overall survival is up to 33 months.

      Conclusion:
      Endostar combined with chemotherapy and endostar maintenance treatment is effective and safe for the treatment of extensive small-cell lung cancer.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.